Table 1.

Demographic and clinical features, and SDSC results.

Patient	Sex	Age	Epilepsy	AED	Sleep disorder treatment	DIMS	SBD	AD	SWTD	DOES	SHY	TOTAL
No. 1	F	1y	Yes	No therapy	–	41	51	47	50	46	51	45
No. 2	F	1y	No	–	–	60	45	47	75	42	69	62
No. 3	F	1y, 5m	No	–	–	64	51	47	66	64	45	64
No. 4	M	1y, 5m	No	–	–	73	86	47	41	64	64	70
No. 5	M	2y, 4m	Yes	VGB, VPA	Melatonin	79	100	70	84	81	69	99
No. 6	F	6y	No	–	Melatonin	66	100	94	100	69	69	100
No. 7	M	7y, 3m	Yes	CBZ	–	70	100	100	75	73	45	90
No. 8	F	11y 6m	Yes	VPA	–	60	45	70	58	88	45	69
No. 9	F	11y, 10m	No	N/A	–	60	45	70	41	50	45	51
No. 10	F	12y, 1m	Yes	CBZ	–	70	86	47	41	53	45	62
No. 11	F	13y, 7m	Yes	VPA, CBZ	–	64	58	58	79	58	45	68
No. 12	M	14y, 4m	No	–	–	66	58	70	58	50	45	62
No. 13	M	16y, 4m	Yes	PB, LEV, VGB, CBZ	–	100	100	70	41	77	69	100
No. 14	M	17y, 4m	Yes	LEV, CBZ	Melatonin	73	86	47	50	42	45	62
MEDIAN (IQR)						66 (11.25)	72 (45.5)	64 (23)	58 (31.75)	61 (22)	45 (22.75)	66 (23)

AED, anti–epileptic drugs; VPA, valproic acid; VGB, vigabatrin; CBZ, carbamazepine; PB, phenobarbital; LEV, levetiracetam. For all patients, the melatonin dosage ranged from 2 to 5 mg.